Press-release for stocks related to clinical-trials-phase-iii for jnj

Prices are updated after-hours

tags : Clinical-trials-phase-iii symbols : Jnj

save search

We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for Inclusivity
Published: 2024-02-22 (Crawled : 09:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -5.65% | O: 0.59% H: 1.11% C: 0.92%
LLY | News | $745.69 1.96% -0.16% 2M

Health Technology

| -1.95% | O: 2.37% H: 1.51% C: 0.79%

TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -7.38% | O: 0.6% H: 0.0% C: 0.0%
tremfya rapid psoriasis clearance study

J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myel...
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -3.7% | O: -0.71% H: 0.0% C: 0.0%
darzalex eye faspro

Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -1.46% | O: 0.64% H: 0.02% C: -0.66%
PTGX S | $26.82 0.79% 0.78% 340K

Health Technology

| 54.44% | O: -0.58% H: 2.19% C: 1.69%
jnj-2113 psoriasis

New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement
Published: 2023-10-23 (Crawled : 12:30) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -2.11% | O: 0.28% H: 0.0% C: 0.0%
tremfya response results show

Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published: 2023-10-12 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -15.85% | O: -0.97% H: 0.0% C: 0.0%
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -6.04% | O: -1.87% H: 0.0% C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M

Health Technology

| 20.83% | O: 0.54% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -15.62% | O: 0.14% H: 0.0% C: 0.0%
trial

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?
Published: 2023-09-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -8.93% | O: 0.15% H: 0.51% C: -1.54%
biotech potential

Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT®
Published: 2023-09-06 (Crawled : 17:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -7.13% | O: -0.37% H: 0.0% C: 0.0%
rybrevant study

Novartis Cuts “Unique” Obesity Drug After Poor Phase II Results
Published: 2023-07-18 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -6.26% | O: 0.0% H: 1.14% C: -0.01%
obesity drug novartis results

Neumora Races Toward Phase III with New Driver in the Hot Seat
Published: 2023-07-18 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -6.26% | O: 0.0% H: 1.14% C: -0.01%

Untangling the Amyloid-Tau Connection to Inform New Drug Development
Published: 2023-07-14 (Crawled : 05:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -6.1% | O: 0.23% H: 0.66% C: 0.43%
drug

Janssen Announces BALVERSA® (erdafitinib) Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma
Published: 2023-06-05 (Crawled : 13:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -5.0% | O: -0.14% H: 1.21% C: 1.0%
balversa

First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
Published: 2023-05-09 (Crawled : 20:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -8.13% | O: -0.35% H: 0.23% C: -0.43%
tremfya disease active positive results show

FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
Published: 2023-04-27 (Crawled : 13:20) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -8.3% | O: 0.17% H: 0.31% C: 0.06%
fda lynparza

AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica
Published: 2023-04-10 (Crawled : 13:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -9.71% | O: -0.31% H: 0.13% C: -0.19%
imbruvica

J&J Drops Out of RSV Race, Cuts Late-Stage Vaccine Candidate
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -2.73% | O: 0.18% H: 0.14% C: -0.1%
candidate vaccine rsv

ArriVent Snags $155M for NSCLC Treatment in Record Low Series B Period
Published: 2023-03-27 (Crawled : 17:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -2.31% | O: 1.02% H: 0.22% C: -0.58%
treatment

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2023-01-27 (Crawled : 21:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -11.71% | O: -0.21% H: 0.19% C: -0.18%
carvykti treatment study

Geron Announces Positive Phase III Data, Likely to Seek FDA Approval in MDS
Published: 2023-01-04 (Crawled : 17:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology